Unknown

Dataset Information

0

Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization.


ABSTRACT: Monoacylglycerol O-acyltransferase 2 (MGAT2) catalyzes the synthesis of diacylglycerol (DG), a triacylglycerol precursor and potential peripheral target for novel anti-obesity therapeutics. High-throughput screening identified lead compounds with MGAT2 inhibitory activity. Through structural modification, a potent, selective, and orally bioavailable MGAT2 inhibitor, compound A (compA), was discovered. CompA dose-dependently inhibited postprandial increases in plasma triglyceride (TG) levels. Metabolic flux analysis revealed that compA inhibited triglyceride/diacylglycerol resynthesis in the small intestine and increased free fatty acid and acyl-carnitine with shorter acyl chains than originally labelled fatty acid. CompA decreased high-fat diet (HFD) intake in C57BL/6J mice. MGAT2-null mice showed a similar phenotype as compA-treated mice and compA did not suppress a food intake in MGAT2 KO mice, indicating that the anorectic effects were dependent on MGAT2 inhibition. Chronic administration of compA significantly prevented body weight gain and fat accumulation in mice fed HFD. MGAT2 inhibition by CompA under severe diabetes ameliorated hyperglycemia and fatty liver in HFD-streptozotocin (STZ)-treated mice. Homeostatic model assessments (HOMA-IR) revealed that compA treatment significantly improved insulin sensitivity. The proximal half of the small intestine displayed weight gain following compA treatment. A similar phenomenon has been observed in Roux-en-Y gastric bypass-treated animals and some studies have reported that this intestinal remodeling is essential to the anti-diabetic effects of bariatric surgery. These results clearly demonstrated that MGAT2 inhibition improved dyslipidemia, obesity, and diabetes, suggesting that compA is an effective therapeutic for obesity-related metabolic disorders.

SUBMITTER: Take K 

PROVIDER: S-EPMC4777574 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization.

Take Kazumi K   Mochida Taisuke T   Maki Toshiyuki T   Satomi Yoshinori Y   Hirayama Megumi M   Nakakariya Masanori M   Amano Nobuyuki N   Adachi Ryutaro R   Sato Kenjiro K   Kitazaki Tomoyuki T   Takekawa Shiro S  

PloS one 20160303 3


Monoacylglycerol O-acyltransferase 2 (MGAT2) catalyzes the synthesis of diacylglycerol (DG), a triacylglycerol precursor and potential peripheral target for novel anti-obesity therapeutics. High-throughput screening identified lead compounds with MGAT2 inhibitory activity. Through structural modification, a potent, selective, and orally bioavailable MGAT2 inhibitor, compound A (compA), was discovered. CompA dose-dependently inhibited postprandial increases in plasma triglyceride (TG) levels. Met  ...[more]

Similar Datasets

| S-EPMC2786494 | biostudies-literature
| S-EPMC7498633 | biostudies-literature
| S-EPMC4027984 | biostudies-literature
| S-EPMC4306691 | biostudies-literature
| S-EPMC124292 | biostudies-literature
| S-EPMC3329399 | biostudies-literature
| S-EPMC8943211 | biostudies-literature
| S-EPMC3265875 | biostudies-literature
| S-EPMC3327653 | biostudies-literature
| S-EPMC4941543 | biostudies-literature